SE9902935D0 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
SE9902935D0
SE9902935D0 SE9902935A SE9902935A SE9902935D0 SE 9902935 D0 SE9902935 D0 SE 9902935D0 SE 9902935 A SE9902935 A SE 9902935A SE 9902935 A SE9902935 A SE 9902935A SE 9902935 D0 SE9902935 D0 SE 9902935D0
Authority
SE
Sweden
Prior art keywords
pharmaceutical compositions
active ingredient
propylsulphonyl
phenylethoxy
benzothiazol
Prior art date
Application number
SE9902935A
Other languages
Swedish (sv)
Inventor
John Dixon
Philip Holt
Francis Ince
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Priority to SE9902935A priority Critical patent/SE9902935D0/en
Publication of SE9902935D0 publication Critical patent/SE9902935D0/en
Priority to AU64604/00A priority patent/AU6460400A/en
Priority to PCT/GB2000/003118 priority patent/WO2001012167A2/en

Links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a pharmaceutical composition, pharmaceutical product or kit comprising a first active ingredient (A) being 4-hydroxy-7-[2-[2-[3-[2-phenylethoxy]propylsulphonyl]ethylamino]ethyl]-1,3-benzothiazol-2(3<i>H</i>)-one or a pharmaceutically acceptable salt thereof, and a second active ingredient (B) being an anticholinergic muscarinic antagonist, for use in the treatment of obstructive airways diseases.
SE9902935A 1999-08-18 1999-08-18 Pharmaceutical compositions SE9902935D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE9902935A SE9902935D0 (en) 1999-08-18 1999-08-18 Pharmaceutical compositions
AU64604/00A AU6460400A (en) 1999-08-18 2000-08-14 Pharmaceutical compositions
PCT/GB2000/003118 WO2001012167A2 (en) 1999-08-18 2000-08-14 Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and an anticholinergic muscarinic antagonist

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9902935A SE9902935D0 (en) 1999-08-18 1999-08-18 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
SE9902935D0 true SE9902935D0 (en) 1999-08-18

Family

ID=20416693

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9902935A SE9902935D0 (en) 1999-08-18 1999-08-18 Pharmaceutical compositions

Country Status (3)

Country Link
AU (1) AU6460400A (en)
SE (1) SE9902935D0 (en)
WO (1) WO2001012167A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
DE10063957A1 (en) * 2000-12-20 2002-06-27 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics and dopamine agonists
DE10111843A1 (en) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Compounds for the treatment of inflammatory diseases
JP4851937B2 (en) 2003-11-21 2012-01-11 セラヴァンス， インコーポレーテッド Compounds having β2 adrenergic receptor agonist activity and muscarinic receptor antagonist activity
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702385D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
CN102124003A (en) 2008-06-18 2011-07-13 阿斯利康(瑞典)有限公司 Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211172D0 (en) * 1992-05-27 1992-07-08 Fisons Plc Compounds

Also Published As

Publication number Publication date
WO2001012167A2 (en) 2001-02-22
AU6460400A (en) 2001-03-13
WO2001012167A3 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
DE60228857D1 (en) AMINO PHTALAZINONE DERIVATIVES, USE AS KINASE INHIBITORS, PREPARATION AND PHARMACEUTICAL COMPOSITION
FR2808685B1 (en) PHARMACEUTICAL COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ANTI-INFLAMMATORY AGENTS
FR2673538B1 (en) COMPOSITION BASED ON 3- [2- (DIMETHYLAMINO) ETHYL] -N-METHYL-1H-INDOLE-5 METHANESULFONAMIDE FOR ORAL ADMINISTRATION.
BR0210122A (en) Compound or a pharmaceutically acceptable salt thereof, method for treating or preventing a disease, use of the compound or salt thereof, and method for preparing the same
EA200301165A1 (en) Drug on the basis of oxycodone
MXPA04000920A (en) Aminoisoxazole derivatives active as kinase inhibitors.
WO2002085909A8 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
CA2229597A1 (en) Oral fast-dissolving compositions for dopamine agonists
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
SE9902935D0 (en) Pharmaceutical compositions
PT1240165E (en) INHIBITORS N- [5 - [[[5-ALKYL-2-OXAZOLYL] METHYL] THIO] -2-THIAZOLYL] CARBOXAMIDE OF CYCLINE DEPENDENT KINASES
BR0108435A (en) Formulation and use of low dose entecavir
SE0102036D0 (en) Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
EE05127B1 (en) A kit of parts and a pharmaceutical preparation containing a P2T receptor antagonist or a pharmaceutically acceptable derivative thereof and an antithrombotic agent and their use in medicine
SE9902937D0 (en) Pharmaceutical compositions
SE9903995D0 (en) New combination
HU9802897D0 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
CA2364178A1 (en) N-benzenesulfonyl l-proline compounds as bradykinin antagonists
SE9902938D0 (en) Pharmaceutical compositions
SE9902936D0 (en) Pharmaceutical compositions
TR200103144T2 (en) New compounds
EE200100596A (en) Highly pure (1R, 2S, 4R) - (-) - 2 - [(2 &#39;- {N, N-dimethylamino} ethoxy)] - 2- [phenyl] -1,7,7-tri [methyl] bicyclo [2.2 .1] heptane and the pharmaceutically acceptable acid addition salts thereof, and the like compounds, as well as drugs containing one or more of said compounds
SE0001916D0 (en) Novel formulation
HUP0402092A2 (en) Use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts for preparation of pharmaceutical compositions